Citations

Clear

334 citation(s) found for "Jacobs, C".

Is There a Unified Etiology of Hypoplastic Left Heart Syndrome? Evaluating Genetic, Structural, and Hemodynamic Models of Disease Initiation
Leonhard, R., Phillips, Zachary Beau, Wilson, Jamie, Abu-Mowis, Zaid, DiGiorgi, John, Wilson, Epiphany N., Borenstein, Zane , Wilson, Laura, Tang, Richard , Stephens, Elizabeth H., Crucean, Adrian , Shillingford, Michael , Peek, Giles J. , Bleiweis, Mark Steven, Alexander, J Steven , Jacobs, Jeffrey Phillip, Alexander, J. Steven , Abu-Mowis, Zaid, Stephens, Elizabeth H. , Crucean, Adrian C. , Bleiweis, Mark Steven

Mayo Clinic

Pathophysiology | May 20, 2026 | Volume: 33 | Issue: 2 | Pages: 33

10.3390/pathophysiology33020033 | PMID 42200818 Get It

Background: Hypoplastic left heart syndrome (HLHS) is defined as “a spectrum of congenital cardiovascular malformations with normally aligned great arteries without a common atrioventricular junction, characterized by underdevelopment of the left heart with significant hypoplasia of the left ventricle including atresia, stenosis, or hypoplasia of the aortic or mitral valve, or both valves, and hypoplasia of the ascending aorta and aortic arch”. Without treatment, HLHS is usually lethal in the neonate. Many hypotheses have been advanced to explain the etiology of HLHS; however, no single theory appears to fully explain the phenotypic variability seen in HLHS. Furthermore, many of these theories offer no explanations regarding the precipitating events which lead to the development of HLHS. Objective: This review considers and critically evaluates the strengths and weaknesses of the leading theories proposed to explain the pathogenesis of HLHS—including hemodynamic disturbances, primary myocardial structural defects, valvar malformations, and genetic or epigenetic alterations that may provoke developmental and anatomic abnormalities. After presenting each model, we propose a novel, comprehensive, and data-driven framework which may assist researchers in developing models for the pathogenesis of the various subtypes of HLHS. Methods: Key findings from human fetal imaging, histopathology, genetic studies, and animal models were considered, as well as the hypothetical contribution of each in observed HLHS phenotypes. The rationales for these findings as causal factors initiating individual HLHS patterns, as well as how they might contribute to HLHS in general, were critically analyzed. Results: The flow theory is strongly supported by animal models and in utero interventions that demonstrate the impact of altered hemodynamics on cardiac morphogenesis. However, the flow theory fails to identify initial causes of disturbed flow or related histological features of HLHS like endocardial fibroelastosis. The myocardial and valve-first models suggest an important role in developmental defects, but do not necessarily have a strong experimental basis that provides explanations for how they mediate HLHS. Genetic studies in patients with HLHS have identified several candidate causal mutations. However, such genetic causes of HLHS exhibit incomplete phenotypic penetrance and clinical impact. A multifactorial framework attempts to integrate these diverse mechanisms and may provide the most coherent explanation that can accommodate the heterogeneity and variable presentation of HLHS. Such a framework may identify multiple forces that drive disease but does not provide useful pathways for future research about HLHS. Conclusions: No single hypothesis has fully explained how HLHS is initiated, progresses, and presents with the clinical conditions that are encountered by cardiac surgeons and cardiologists. The most current models suggest that the spectrum of HLHS reflects acomplex interaction between genetic susceptibility, flow-dependent cardiac remodeling, and environmental factors in utero. A multifactorial model integrates these diverse mechanisms and may provide the most coherent explanation for the various phenotypic variations in HLHS. Based on our analysis of the most current data and the strengths and weaknesses of the current theoretical frameworks, we propose a novel research strategy aimed at identifying specific cardiac progenitor cell populations whose dysregulation may represent a unifying explanation for the etiology of the various phenotypes of HLHS. Based on the arguments made throughout this manuscript that evaluate the various genetic, structural, and hemodynamic models of initiation of disease, we believe that the significant phenotypic variability across the spectrum of HLHS (i.e., the different anatomic subtypes for “classic” HLHS) most likely reflects different underlying etiologies and mechanisms. At the very least, it is very likely that the timing of the insult is critical in determining anatomic subtype. Based on the published data and the arguments within this manuscript, it seems naive to think that there is a single unifying mechanism explain all forms of HLHLS.
Virulence factors released by Staphylococcus aureus induce oxidative stress which stimulates ATP release, Ca 2+ mobilization and IL-33 secretion in human airway epithelial cells
Srisomboon, Yotesawee, Hunter, Ryan, Kita, Hirohito, O'Grady, Scott, Hunter, Ryan C. , Kita, Hirohito

Mayo Clinic

Physiology | May 12, 2026 | Volume: 41 | Issue: S1 | Pages: No page available

10.1152/physiol.2026.41.s1.2294883 Get It

Staphylococcus aureus is a well-known pathogen responsible for a wide range of diseases with life-threatening consequences. Its public health burden continues to be significant due to pervasive colonization and growing antimicrobial-resistance (i.e., methicillin-resistant S. aureus, MRSA). In the present study we found that exposure of human bronchial epithelial (hBE) cells to spent culture supernatants of the MRSA strain USA300 induced an increase in mitochondrial ROS production and ATP release that was inhibited by pretreatment with the ROS scavenger glutathione (GSH). ATP secretion involved activation of probenecid-sensitive pannexin 1 channels and bafilomycin A1-dependent exocytosis. ATP exocytosis was inhibited by an antagonist peptide targeting the Receptor for Advanced Glycation End (RAGE) products suggesting that RAGE activation was involved in regulating vesicular ATP release. ATP secretion produced a sustained increase in intracellular Ca 2+ concentration which was dependent upon Ca 2+ uptake from the extracellular solution. Moreover, the sustained JE2-induced Ca 2+ response was not observed in spent supernatants from the less virulent S. aureus agrA mutants used to stimulate hBE cells whereas media from fadX and codY mutants produced responses similar to JE2. Furthermore, wildtype, fadX and codY supernatants evoked secretion of the type-2 inflammatory cytokine IL-33, whereas no response was elicited by media from the less virulent argA mutant. These findings indicate that exposure to secreted virulence factors from S. aureus induces oxidative stress in hBE cells that leads to ATP secretion, sustained Ca 2+ uptake and IL-33 secretion, which has been previously shown to induce type-2 inflammation in airways. This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.
Predictors for Type 2 Endoleak Requiring Embolization: Large Inferior Mesenteric Artery, Multiple Lumbar Arteries, and Anticoagulation
Esquetini-Vernon, Camila , Farres, Houssam, Sandoval, Camilo Polania, Ritchie, Charles, Jacobs, Christopher, Toskich, B., Fumagalli, Ricardo Paz, Erben, Young, Polania Sandoval, Camilo, Paz Fumagalli, Ricardo, Esquetini-Vernon, Camila , Farres, Houssam , Ritchie, Charles , Jacobs, Christopher, Paz‐Fumagalli, Ricardo , Erben, Young

Mayo Clinic

Vascular and Endovascular Surgery | May 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15385744261450590 | PMID 42091579 Get It

Introduction Endovascular abdominal aortic aneurysm repair (EVAR) is the primary treatment for abdominal aortic aneurysm (AAA). Despite favorable early outcomes, lifelong surveillance is essential as endoleaks remain a major cause of reintervention. Among these, type II endoleaks (T2E) remain controversial regarding optimal management. This study aimed to identify factors associated with intervention for T2E using time-to-event analysis and predefined anatomic thresholds. Secondary objectives included comparing outcomes between T2E patients with (intT2E) and without (nointT2E) intervention. Methods A retrospective review of EVAR procedures from 2011-2024 was performed. Patients with newly diagnosed or persistent T2E were identified on completion and follow-up CT angiography. Patients were categorized as intT2E or nointT2E. Multivariable Cox regression evaluated time to first intervention, and logistic regression served as sensitivity analysis. Kaplan-Meier curves assessed freedom from intervention by inferior mesenteric artery (IMA) size. Results Among 207 EVAR patients, 78 (37.6%) developed T2E over a mean 3.4 ± 2.4 years. Nineteen (24.3%) required intervention. IntT2E patients were younger (74.9 ± 6.8 vs 78.3 ± 7.9 years, P = 0.02), had more frequent anticoagulation use (47.4% vs 20.3%, P = 0.02), larger IMAs (4.2 ± 0.6 vs 3.3 ± 0.7 mm, P < 0.01), and more lumbar arteries (6.0 ± 1.2 vs 5.0 ± 1.3, P = 0.02). IMAs >4 mm occurred in 68.4% of intT2E vs 8.5% of nointT2E ( P < 0.01). Mean sac growth was greater in intT2E (9.7 ± 5.3 mm vs −1.9 ± 6.5 mm, P < 0.01). Thirty-day complications following the index EVAR procedure, mid-term reinterventions, and overall mortality were similar between groups. Post-embolization, T2E resolved in 36.9%, with sac regression in 63.1%. Among embolized patients, 26.3% required a second embolization and one patient required 3 attempts without achieving resolution. IMA >4 mm independently predicted intervention (HR 7.18, 95% CI 1.97-26.16, P < 0.01). Logistic regression confirmed IMA >4 mm (OR 23.4, 95% CI 6.17-88.6, P < 0.01), >6 lumbar arteries (OR 4.2, 95% CI 1.10-15.98, P = 0.02), and anticoagulation (OR 3.4, 95% CI 1.17-10.6, P = 0.02) as predictors. Conclusions Approximately one-quarter of T2E patients required embolization. IMA >4 mm was the strongest predictor of intervention, while anticoagulation and increased lumbar artery number also increased risk. Management should prioritize risk-stratified surveillance and selective intervention.
Soluble Thrombomodulin Links Viremia and Mortality During COVID‐19: Results From the ACTIV‐4a Trial
Zuchelkowski, Benjamin E. , Inman, Kyle, Nouraie, S Mehdi, Beru, Neeharika, Naqvi, Asma , Qin, Shulin, Yeh, Calvin H., Zhang, Yingze , Shah, Faraaz , Sharma, Lokesh , Zhang, Lianghui , Morris, Alison, Kim, Paul Y., Jacobs, Jana L. , Nouraie, Mehdi , Inman, Kyle W , Nouraie, Seyed Mehdi , Shah, Faraaz A , Zhang, Lianghui , McVerry, Bryan J , Morris, Alison , Neal, Matthew D , Seheult, Jansen N , Kitsios, Georgios D , Mellors, John W , Lawrence, Daniel A , Kim, Paul Y , Jacobs, Jana L , Bain, William G , Zhang, Yingze , Inman, Kyle , Naqvi, Asma , Qin, Shulin , Yeh, Calvin H., Sharma, Lokesh , Dela Cruz, Charles S , Seheult, Jansen N.

Mayo Clinic

Journal of the American Heart Association | May 6, 2026 | Volume: 15 | Issue: 10 | Pages: No page available

10.1161/jaha.125.047693 | PMID 42089155 Get It

Background COVID‐19 and other respiratory viral infections can cause cardiovascular complications. SARS‐CoV‐2 virions are found in the blood, and circulating viral RNA levels are associated with death. We hypothesized that viremia can induce thrombotic endotheliopathy that contributes to death and studied this relationship in patients hospitalized for COVID‐19 and enrolled in the ACTIV‐4a (Accelerating COVID‐19 Therapeutic Interventions and Vaccines) randomized trial of antithrombotic therapy. Methods We quantified SARS‐CoV‐2 nucleocapsid RNA and protein in plasma and measured their associations with clinical outcomes and biomarkers of thromboinflammation and endotheliopathy. We used Cox regression and Fine–Gray competing risk models to analyze survival and thrombosis. We conducted causal mediation analysis to explore whether thrombotic endotheliopathy mediates the relationship between viral RNA and death. Results In 93 patients, SARS‐CoV‐2 RNA and N‐antigen were higher in nonsurvivors. Baseline viral RNA levels were associated with increased 90‐day death (hazard ratio [HR], 1.31 [95% CI, 1.17–1.46]) and thrombosis (HR, 1.35 [95% CI, 1.24–1.47]). Viral RNA more effectively predicted survivorship than N‐antigen levels. Soluble thrombomodulin, a biomarker of thrombotic endotheliopathy, positively correlated with viral RNA levels. Mediation analysis revealed that soluble thrombomodulin accounts for 12.2% (95% CI, 0.1%–32.3%; P =0.048) after adjustment for age and sex of the relationship between viral RNA and the 90‐day mortality rate. Conclusions Elevated plasma SARS‐CoV‐2 RNA levels are associated with death in ACTIV‐4a, which is causally mediated in part by soluble thrombomodulin. We propose that lung–blood viral dissemination is a potential mechanism for cardiovascular complications of respiratory viruses. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04505774.
Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease
Rae, Rosaria J., Alberhasky, Jessica Marie Hunter, Bangasser, Debra A. , Berteotti, Chiara, Bow, Hannah, Caldwell, Jessica Z. K., Carpi, Matteo , Ciampa, Claire J., Ehrenberg, Alexander J. , Fenlon, Haley A., Fitzhugh, Megan C. , Gallay, Clara , Hamilton, Derek A. , Hasan, Zia , Huarte, Oihane Uriarte , Jabeen, Shaista , Kolling, Louis John , Liguori, Claudio , Omoluabi, Tamunotonye, Pa, Judy, Pentkowski, Nathan S. , Pereira, Joana B., Ramos, Rhudovic R., Sargin, Derya , Seto, Mabel, Shaik, Shabana M. , Ucheagwu, Valentine , Kelberman, Michael A. , Grinberg, Lea Tenenholz, Satpati, Abhijit, Son, Gowoon, Rae, Rosaria Josephine, Baillet, Marion , Belloy, Michaël E. , Berry, Anne S. , Berteotti, Chiara , Bow, Hannah, Buckley, Rachel F. , Caldwell, Jessica K. , Clark, Benjamin J. , Conley, Alexander C. , Dahl, Martin J. , Donaldson, Zoe R. , Einstein, Gillian , Falgàs, Neus , Froemke, Robert C. , Grinberg, Lea T. , Jacobs, Heidi I.L. , Koops, Elouise A. , Lenzoni, Sabrina , Manca, Riccardo , Marcinkiewcz, Catherine Anne , Omoluabi, Tamunotonye, Oria, Rademene Sunday , Orsini, Caitlin A. , Ortega, Nancy Elizabeth , Pa, Judy , Pereira, Joana B. , Satpati, Abhijit , Sellés, María Clara , Seto, Mabel , Sindi, Shireen , Son, Gowoon , Egroo, Maxime Van , Yuan, Qi

Mayo Clinic

Alzheimer's & Dementia | March 19, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71291 | PMID 41853971 Get It

Abstract Neuromodulatory subcortical systems (NSSs) are uniquely susceptible to dementia‐related pathology, leading to frequent molecular and behavioral impairments associated with altered function of these nuclei. Some of these systems display clear sex‐specific cytoarchitecture and signaling leading to distinct physiology and behavioral outputs in males and females, while other regions display nominal sex differences. However, the relevance of sex differences in modulating dysfunction of NSSs in Alzheimer's disease (AD) and related dementias is not well understood. This review is a joint effort by the Neuromodulatory Subcortical Systems and Sex and Gender Differences in Alzheimer's Disease Professional Interest Areas of the Alzheimer's Association. We review sex differences in NSSs, both in non‐disease states and in AD models and patients. We highlight the possible role of NSSs in driving sex‐specific AD susceptibility and potential footholds for sex‐based interventions targeting these systems. We conclude by outlining immediate and long‐term actions to address the intersection of NSSs, sex, and AD.
TNF-α blockade mitigates immune checkpoint–related nephritis in a humanized mouse model
Narvaez, Victor D Cuenca, Chavez, Coraima Nava, Refai, Omar Al, Gutierrez, Luis E., Zhang, Song, Li, Xiaoyan, Hirdler, Jacob B. , Romero, Michael F. , Herrmann, Joerg, Li, Xiaogang, dong, Haidong, Eirin, Alfonso, Herrmann, Sandra M., Romero, Michael F , Chavez, Coraima Claudia Nava , Jacobs, Johanna E.J., Herrmann, Joerg , Dong, Haidong , Eirin, Alfonso , Herrmann, Sandra M.

Mayo Clinic

JCI Insight | March 5, 2026 | Volume: 11 | Issue: 8 | Pages: No page available

10.1172/jci.insight.199694 | PMID 41785046 Get It

Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs), with acute interstitial nephritis (ICI-AIN) being the most common irAE. While the exact mechanism remains unclear, upregulation of IFN-γ and TNF-α pathways has been implicated. This study used a humanized chimeric PD-1/PD-L1 mouse model to assess renal effects of ICIs, alone or combined with proinflammatory cytokines, and to test if selective TNF-α blockade could prevent ICI-AIN. Mice were randomly divided into 4 experimental groups: Control, ICI-Only, ICI-Cytokines (ICI-Cyt), and ICI-Block (ICI-TNF-α blockade). Renal function and cytokine profiles were assessed, while kidney tissue was analyzed using microscopy and single-cell RNA-seq. Histology revealed increased renal infiltration of CD4 + /CD8 + T cells in ICI-treated groups and decreased TNF-α expression following TNF-α blockade. Additionally, kidney tissue ELISA demonstrated reduced IFN-γ levels following TNF-α blockade. Plasma IL-6, MCP-1, and TNF-α were lower in ICI-Block mice. Single-cell RNA-seq revealed shifts in immune cell populations and genes of interest including Bcl2a1 , Icos , Il18r1 , Ccr2 , and Jaml . This humanized model replicates ICI-AIN key features, revealing a synergistic role of ICIs and proinflammatory cytokines. TNF-α blockade demonstrated protective effects, supporting its potential role in mitigating the risk of ICI-AIN.
Practical application of pressure-volume loop analysis in a swine model of medical cardiac arrest
Jodłowski, Grzegorz , Rousseau, Mathieu, Jacobs, J F, Nelson, J, Dvir, May , Walker, P F, Morrison, J J, Stonko, David P. , Morrison, Jonathan J

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.2190 Get It

Abstract Introduction Cardiac arrest (CA) is the sudden cessation of cardiac activity, leading to haemodynamic collapse and high mortality. Advanced life support (ALS) standardises resuscitation, but the post-return of spontaneous circulation (ROSC) period remains turbulent and poorly understood. Up to 50% of patients who achieve ROSC struggle to maintain spontaneous circulation, leading to re-arrest, typically within minutes. Post-cardiac arrest syndrome (PCAS), involving brain injury and ischaemia-reperfusion injury, plays a key role in re-arrest. Pressure-volume loop (PVL) analysis offers insight into load-independent cardiac biomechanics in the post-ROSC period. The aim of this study is to explore the feasibility of PVL analysis in a swine model of CA. Methods This swine study utilised a ventricular fibrillation (VF) cardiac arrest model in combination with PVL analysis. The experiment included four phases: animal preparation, VF induction, resuscitation, and post-ROSC care. Yorkshire swine (45-70 kg) were sedated, anaesthetised, and VF was induced via an endocavitary electrode attached to a battery. After that, the animals were divided into 3-minute and 6-minute arrest groups before commencing ALS. Standard ALS protocols were followed, including CPR, defibrillation, and drug administration. If ROSC was obtained, animals underwent a 3-hour critical care period. Cardiac indices were compared between baseline and end-of-study values. Results Eight adult Yorkshire swine were enrolled in the study, with a mean weight of 50.2 ± 2.9 kg. VF induction was successfully achieved, and PVL data were collected in all animals except one, establishing a successful porcine VF CA model. In the resuscitation phase, all animals in the 3-minute group achieved ROSC, as opposed to one in the 6-minute group. Post-ROSC metabolic changes included acidaemia, elevated lactate and potassium, partially resolving by study end. Right ventricle PVL data were unreliable, while left ventricle PVL was reliable in 3 of 5 ROSC animals. Preload-recruitable stroke work (PRSW) data were found to be more reliable than the End-Diastolic Pressure-Volume Relationship (ESPVR), with a significant increase in LV PRSW of 34 ± 12% observed post-ROSC in all surviving animals (p&lt;0.001). Discussion This study demonstrates the feasibility of applying PVL analysis to a post-ROSC swine model of cardiac arrest (CA). As expected, warm ischaemic time predicted ROSC, but PVL analysis offered valuable insights into load-independent parameters. While data quality issues hindered ESPVR analysis, PRSW was successfully evaluated, revealing a significant increase post-ROSC, highlighting its potential to guide the development of future therapeutic targets for post-ROSC interventions. The small sample size and technical challenges limited the scope of conclusions, emphasising the need for larger studies.Kaplan-Meier Curve and cycles to ROSC (A) LV PVL, (B) PRSW Pre and Post-ROSC
Establishing Reference Values in Healthy Participants for the Cardiac Troponin T High-Sensitivity Gen 6 Assay: REF-TSIX Global Reference Study
Daniels, Lori B. , Mueller, Christian, Giannitsis, Evangelos, Meex, Steven J. R., Buehlmann, David, Dilba, Peter, Bendig, Garnet, Cole, Mette, Body, Richard, Christenson, Robert H, deFilippi, Christopher R, Inoue, Kenji, Jaffe, A S, McCarthy, Cian P. , McCord, J., Neumann, Johannes T, Omland, T., Papendick, Cynthia , Sandoval, Yader, Twerenbold, Raphael, Peacock, W Frank, Mills, Nicholas L, investigators, the TSIX, Jacobs, Michael B., Lucksinger, Gregg, Powell, Richard, Johnson, Daniel, Coleman, Hugh, Fein, M, Surber, Joseph, Vu, Jack B., Hassman, Michael, Hernandez, John, Kirstein, Judith, Tomaszewski, Christian, Runyon, Michael S. , Gong, Jonathan , Wein, D., Andrabi, Sara , Kopin, David , Larrain, Germain, Tahirkheli, Naheem, Clemency, Brian, Abdullah, Shuaib, Hira, Ravi S. , Klausner, H A, Mahler, Simon A. , Crystal, Chad, Headden, Gary, Chaille, Peter, Cannon, Chad Aaron, Limkakeng, Alexander, Tolia, Vaishal , Knapp, Barry J., Massoomi, Mohammad, Sandoval, Yader, Ko, Emily, Luzzi, Verónica, Christenson, Robert, Carson, Jennifer Powers , Cacioppo, F , Kolev, E., Petrov, Andrey, Hazarbasanov, Dobri , Simova, lana, Magimaiseelan, Luci Suganthi, Kosch, Christine, Klein, G, Mehltretter, Kai, Sauter, Joachim, Baumann, Sybille, Moeckel, Martin, Twerenbold, Raphael, Muller-Hennessen, Matthias, Biener, Moritz , Findeisen, P., Omland, Torbjøm, Wilczek-Kosowska, Urszula, Zimmer-Satora, Ewa, Krecipro-Nizińska, Ewa, Miró, O, Díaz, Víctor Jiménez , Mueller, C, Christ, Michael, Lynch, Stephen, BODY, R. A. F., Matsuki, Shunji, Eto, Takashi, Tanaka, Takanori, Hanada, Ryuzo, Nakagami, Takuo, Nakama, T, Kadota, K., Jing, Shan, Yu, Shuwen, Zhang, Hongxuan, Zhang, Jun, Huo, Yong, Zhang, Yan, Yan, Li, Jiang, Longyuan, Chen, Weiqiang, Huang, Jianying, Zhao, Yan, Guan, Ling, Yang, Yanhua, Zhang, Qin, Qiu, Zhaohui, Body, Richard , Neumann, Franz–Josef , Müller, Christian , Mueller, Christian , Body, Rick , Eggers, Kai M. , Jaffe, Allan S. , Neumann, Johannes T , Sandoval, Yader , Tan, Jack Wei Chieh , Than, Martin , Twerenbold, Raphael , Mills, Nicholas L , Daniels, Lori B , Giannitsis, Evangelos , Meex, Steven J.R. , Christenson, Robert H. , Cobbaert, Christa M. , deFilippi, Christopher R. , McCord, James , Omland, Torbjørn , Sandoval, Yader , Tan, Jack Wei Chieh , Than, Martin , Twerenbold, Raphael , Surber, Joseph, Tomaszewski, Christian, Clemency, Brian, Headden, Gary , Cannon, Chad, Knapp, Barry , Tran, Nam K , Niederdöckl, Jan Daniel , Kolev, Emil, Popov, Todor, Sauter, Joachim, Baumann, Sybille , Möeckel, Martin , Müller‐Hennessen, Matthias, Findeisen, Peter, Scharnhorst, Volkher , Omland, T, Krecipro-Nizińska, Ewa, Christ, Michael , Nakagami, Takuo, Huo, Yong

Mayo Clinic

Clinical Chemistry | January 18, 2026 | Volume: 72 | Issue: 4 | Pages: 488-502

10.1093/clinchem/hvag011 | PMID 41564003 Get It

Abstract Background Measurement of cardiac troponin (cTn) using high-sensitivity assays is recommended for the diagnosis of myocardial infarction. We determined sex-specific and uniform 99th percentile upper reference limits (URLs) using the new Elecsys® Troponin T high-sensitivity Gen 6 assay in a global, healthy reference range cohort. Methods Lithium-heparin plasma and serum samples were prospectively collected from apparently healthy individuals aged ≥20 years across 34 global sites in the United States, Europe, China, and Japan. cTnT was measured using the Troponin T high-sensitivity Gen 6 assay on the Cobas® e 801 analyzer. Exclusion criteria were defined according to the 2022 IFCC guidance. Uniform and sex-specific 99th percentile URLs and nonparametric 95% CIs were determined in plasma and serum separately and combined. Results The final study population comprised 4147 participants (52.5% female) with a median (25th–75th percentiles) age of 48.0 (33.0–59.0) years; 45.8%, 47.9%, 5.2%, and 1.1% were White, Asian, Black, and other/unknown, respectively. For sample matrices combined (n = 8294), 81.0% and 99.2% of cTnT values were above the limit of detection in females and males, respectively. Sex-specific 99th percentile URLs (95% CI) were 18 (16–23) ng/L for females and 32 (28–35) ng/L for males; the uniform 99th percentile URL was 27 (24–31) ng/L. URLs were comparable in plasma and serum samples. Conclusions This study determined sex-specific and uniform 99th percentile URLs for the Troponin T high-sensitivity Gen 6 assay that were comparable irrespective of the matrix used in a large, global, healthy reference population.
Research Code Sharing in Support of Gold Standard Science
Klonoff, David C., Espinoza, Juan, Mader, Julia K., Heinemann, Lutz, Cobelli, Claudio, Kerr, David , Kovatchev, Boris, Najafi, Bijan , Prahalad, Priya , Zheng, Yaguang , Shao, Mandy M. , Scheideman, Agatha F. , DuNova, Ashley Y. , Kohn, Michael , Umpierrez, Guillermo E., Malek, Aiman Abdel, Agus, Michael S. D., Ahn, David T., AlSaad, Rawan , AL-SOFIANI, MOHAMMED, Armstrong, David, Arnold, Mark A., Bequette, B. Wayne , Bellazzi, Riccardo, Cengiz, Eda, Chase, J. Geoffrey, Chen, Jake Y. , Cichosz, Simon Lebech , Clements, Mark A. , Close, Kelly L., Cuadros, Jorge , Contreras, Ivan, Drincic, Andjela , Facchinetti, Andrea, Fleming, G. Alexander , Gabbay, Monica A. L., Healey, Elizabeth, Hoang, Thanh D., Kulzer, Bernhard, Belle, Jeff La, Lee, Aaron, Lee, Cecilia S., Lee, Wei-An , Liepmann, Dorian , Maahs, David M. , Mathioudakis, Nestoras, Metwally, Ahmed A., Mohan, Viswanathan, Moon, Sun-Joon, Raeder, Helge, Rhee, Connie, Rhee, Eun-Jung, Scheinker, David , Shah, Viral N., Snyder, Michael P., Sode, Koji, Spanakis, Elias K., Svensson, Jannet, Vaswani, Nitin, Vareth, Maryam, Wallia, Amisha , Wang, Tao, Williams, Ebonie, Wolf, Ruth, Wong, Jenise C., Yeshiwas, Sewagegn, Shah, Shahid N. , Cobelli, Claudio , Snyder, M , Kovatchev, Boris , Heinemann, Lutz , Espinoza, Juan , Mathioudakis, Nestoras , Mader, Julia K. , Klonoff, David C , Espinoza, Juan , Mader, Julia K , Heinemann, Lutz , Cobelli, Claudio , Kovatchev, Boris , Umpierrez, Guillermo E. , Wong, Tien Y , Abdel Malek, Aiman , Agus, Michael S D , Ahn, David T , AlSaad, Rawan , Al-Sofiani, Mohammed E , Armstrong, David , Arnold, Mark A , Bee, Yong Mong , Bequette, B Wayne , Bellazzi, Riccardo , Cengiz, Eda , Chase, James Geoffrey , Chen, Haipeng , Chen, Jake Y , Cichosz, Simon L , Cinar, Ali , Clements, Mark A , Close, Kelly L , Cuadros, Jorge , Contreras, Ivan , Datta, Gora , Dhatariya, Ketan , Doyle, Francis J , Drincic, Angela , Facchinetti, Andrea , Fleming, G Alexander , Foreman, Joshua , Gabbay, Monica A L , Gutierrez-Osuna, Ricardo , Healey, Elizabeth , Hoang, Thanh D , Jacobs, Peter G , Kulzer, Bernhard , La Belle, Jeff , Lee, Aaron Y , Lee, Cecilia S , Lee, Wei-An Andy , Liepmann, Dorian , Maahs, David M , Mathioudakis, Nestoras N , Meo, Sultan A , Metwally, Ahmed A , Misra, Shivani , Mohan, Viswanathan , Moon, Sun-Joon , Raeder, Helge , Rhee, Connie M , Rhee, Eun-Jung , Scheinker, David , Shah, Viral N , Sheng, Bin , Snyder, Michael , Sode, Koji , Spanakis, Elias K , Svensson, Jannet , Vaswani, Nitin , Vareth, Maryam , Vehi, Josep , Wallia, Amisha , Waki, Kayo , Wang, Tao , Williams, Eric , Wolf, Risa M , Wong, Jenise C , Bekele, Sewagegn Yeshiwas , Zilbermint, Mihail , Shah, Shahid N , Klonoff, David C. , DuBord, Ashley Y., Wong, Tien Yin , Agus, Michael S. D. , Ahn, David , Close, Kelly L. , Dhatariya, Ketan , Doyle, Francis J. , Rhee, Connie M. , Sode, Koji , Spanakis, Elias K. , Waki, Kayo , Wong, Jenise C. , Zilbermint, Mihail

Mayo Clinic

Journal of Diabetes Science and Technology | January 14, 2026 | Volume: 20 | Issue: 3 | Pages: 609-619

10.1177/19322968251391819 | PMID 41532590 Get It

Sharing research code in an open access version-controlled repository offers significant benefits for both science as a whole and for individual researchers. In this article, we focus on this practice, which is fully aligned with the NIH’s Gold Standard Science (GSS) program as well as FAIR (findable, accessible, interoperable, reusable) and TRUST (transparency, responsibility, user focus, sustainability, technology) principles. Gold Standard Science supports open science by emphasizing transparency, reproducibility, and the use of best practices that enable others to verify and extend research. Pairing a research article’s cited data snapshot with a versioned, environment-specific code release, deposited in a companion code repository, ensures that, upon submission to a medical journal, readers and reviewers can directly verify results. An executable and updatable companion code repository complements, rather than replaces, established research data repositories. When code underlying medical research results is made openly available, then other scientists can inspect, run, and validate analyses. These activities enhance reproducibility, which is a core aim of GSS. Shared code also facilitates collaborative innovation by allowing researchers to extend the utility of the code to new datasets and applications. For researchers, code sharing can increase visibility, credibility, and citation impact. Demonstrating transparency through shared executable and updatable code builds trust with journal readers, peer reviewers, funders, and peers. Shared code in an open access repository signals adherence to high standards of scientific integrity and attracts opportunities for collaboration. A researcher who shares code receives recognition as a leader in reproducible, trustworthy research consistent with NIH’s GSS principles.
629. Investigating the Molecular Epidemiology of Extended-Spectrum β-Lactamase Producing Enterobacterales Among Patients Admitted to the Intensive Care Unit
Sharara, Sima L. , Simner, Patricia J. , Jacobs, Emily, Fiawoo, Suiyini, Cosgrove, Sara E, Tamma, Pranita, Sharara, Sima L. , Bergman, Yehudit , Klein, Eili Y. , Cosgrove, Sara E. , Tamma, Pranita D.

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.196 Get It

Abstract Background Colonization with extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) is increasingly recognized in critically ill patients and impacts infection prevention practices and empiric antibiotic selection. However, contemporary United States estimates of ESBL-E prevalence at the time of ICU admission are limited.Table 1.ICU-Specific Prevalence of ESBL Colonization at Admission Confirmed by Whole Genome SequencingFigure 1.Distribution of ESBL Gene Variants Among ESBL-Producing Enterobacterales Isolates by Bacterial Species (n = 173) Methods We conducted a prospective molecular epidemiology study of ESBL-E colonization among adult and pediatric patients admitted to nine ICUs at The Johns Hopkins Hospital between March and August 2023. Routine rectal surveillance swabs (Copan Eswab) collected at ICU admission were plated on selective chromogenic media (HardyCHROM™ ESBL) to identify third-generation cephalosporin-resistant Enterobacterales (3GCRE). Species identification was performed using MALDI-TOF MS, and ceftriaxone resistance was confirmed by broth microdilution. Whole-genome sequencing (WGS) was performed on the first isolate of each species per patient to confirm ESBL gene carriage and assess molecular features. Results Among 3,278 ICU admissions, 328 (10%) had 3GCRE isolated on admission swabs. Of these isolates, 173 (5% of all admissions) were confirmed by WGS to harbor at least one ESBL gene—representing approximately 53% of all 3GCRE isolates. ESBL-E colonization was most prevalent in the medical (10%) and cardiac (8%) ICUs. The most common ESBL-E species were Escherichia coli (72%) and Klebsiella pneumoniae (19%). Dominant E. coli sequence types were ST131 (36%), ST1193 (7%), and ST38 (6%). Nearly all ESBL genes belonged to the blaCTX-M family (95%), with blaCTX-M-15 as the predominant allele (63%). Other ESBL genes included blaCTX-M-27 (17%), blaCTX-M-14 (5%), blaCTX-M-55 (5%), and blaSHV-12 (3%). Conclusion In this large, prospective cohort, 5% of ICU patients were colonized with ESBL-E at admission, most commonly E. coli and K. pneumoniae harboring blaCTX-M genes. Phenotypic detection of 3GCRE overestimated ESBL-E prevalence by nearly 90%, highlighting the need for molecular confirmation to accurately characterize resistance. These findings suggest ESBL-E colonization remains uncommon in the U.S., even at a major referral center, supporting non-carbapenem empiric therapy in low-risk patients and reinforcing the need for targeted surveillance. Disclosures All Authors: No reported disclosures